RESULTS: A total of 167 patients were included after exclusion criteria. Median age was 73 years-old. Stage repartition was 146 (87%) cT2, 11 (6,5%) cT3 and 10 (6%) cT4. Neoadjuvant chemotherapy was given in 31 (18,5%) patients. RT alone was administered in 8 (5%) patients and 159 (95%) received trimodal therapy. Post treatment cystoscopy and cytology were normal in 148 (87%) patients (Flow chart). Seventy-two (43%) underwent biopsy to assess response. Of these patients, a for-cause biopsy was performed in 13 (68%) patients whereas 53 (36%) had a control biopsy in the setting of normal cystoscopy and cytology. For cause biopsy demonstrated residual MIBC in 7 (36%), NMIBC in 2 (10%), and benign histology in 10 (52%). Control biopsy demonstrated residual MIBC in 4 (7%), NMIBC in 5 (9%), and benign histology in 44 (83%).
INTRODUCTION AND OBJECTIVES:
Opioids are frequently overprescribed after urological surgery. The 2018 AUA position statement on opioid use suggests using the lowest dose and potency to achieve post-operative pain control, but a lack of procedure-specific prescribing guidelines contributes to wide variation in prescribing patterns. This study addresses this gap through an expert panel consensus.
METHODS: A 15-member multidisciplinary expert panel included representatives from 5 stakeholder groups (attending urologists, multispecialty fellows, residents, nurse practitioners, and patients). We used a 3-step modified Delphi method to develop consensus recommendations for opioid prescribing after 9 minimallyinvasive procedures, encompassing transurethral surgery and laparoscopic and robotic kidney and prostate surgery for benign and malignant disease. Recommendations were made for opioid-naive patients without chronic pain conditions. The panel used oxycodone 5 mg equivalents to define the number of prescribed tablets.
RESULTS: Procedure-specific recommendations were developed for all 9 procedures. The panel agreed that not all patients desire or require opioids after surgery; thus, the minimum recommended number of opioids for all procedures was 0 tablets. The maximum number of opioids varied by procedure, from 0 tablets for 2 of the 9 procedures, to 15 tablets (mean 10.6 tablets). For the majority of procedures, nurses and trainees voted for lower opioid quantities than attending urologists. The panel developed 8 strategies for opioid stewardship: 1) Prescribing is a shared decision with patients, and opioids should not be prescribed to patients who express a preference not to use them; 2) Consider clinical factors affecting a patient's expected response to opioids; 3) Maximize non-opioid agents, including acetaminophen and NSAIDs, for baseline pain control, unless contraindicated; 4) In patients hospitalized after surgery, consider how frequently they have used opioids to achieve adequate pain control, to anticipate post-discharge needs; 5) Query prescription drug monitoring programs where available; 6) Patients should be provided information about safe opioid storage and disposal; 7) Prior to refilling opioids, assess patterns of pain management and consider postoperative complications; 8) Patients with chronic pain may have needs beyond the scope of these recommendations.
CONCLUSIONS: Procedure-specific guidelines for prescribing opioids after minimally-invasive surgery may help clinicians align individual prescribing habits with consensus recommendations. These guidelines can aid quality improvement efforts to reduce overprescribing in urology.
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PD58-02 OVER USE OF OPIOIDS AFTER PROSTATECTOMY: STATEWIDE EXPERIENCE FROM THE MICHIGAN UROLOGIC SURGERY IMPROVEMENT COLLABORATIVE (MUSIC)
Parth Shah*, Ji Qi, Stephanie Ferrante, David Miller, M.Hugh Solomon, Ann Arbor, MI; Jason Hafron, Richard Sarle, Troy, MI; Brian Lane, Sabrina Noyes, Grand Rapids, MI; James Peabody, Detroit, MI; Alex Hallway, William Palazzolo, Tae Kim, Susan Linsell, Ann Arbor, MI; Ivan Rakic, East Lansing, MI; James Dupree, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI INTRODUCTION AND OBJECTIVES: Opioid over prescription is a well described phenomenon in medicine; urology is no exception. Prior research has described this on an institutional basis. However, little is known about urologic opioid prescribing patterns on a statewide level. Here we present opioid prescription and consumption patterns after robot assisted radical prostatectomy (RARP) in the Michigan Urologic Surgery Improvement Collaborative (MUSIC).
METHODS: MUSIC is a consortium of 42 urology practices, both academic and private, that maintains a prospective registry of validated clinical data, including patient reported outcomes. In June 2018, opioid use was discussed in the collaborative and an initiative was implemented to monitor opioid use among RARP patients with the aim of reducing opioid prescription. All patients undergoing RARP in the Patient Reported Outcomes program were eligible to participate. A baseline survey captured opioid use and pain levels before surgery. A second survey at 30 days post RARP captured prescription quantity and type, opioid consumption and refills, current pain levels, and ongoing opioid use. Opioids were converted to morphine milligram equivalents (MME) to standardize analyses.
